BTIG Research Cuts Abbott Laboratories (NYSE:ABT) Price Target to $140.00

Abbott Laboratories (NYSE:ABT) had its target price reduced by BTIG Research from $145.00 to $140.00 in a report published on Tuesday morning,MarketScreener reports. They currently have a buy rating on the healthcare product maker’s stock.

ABT has been the topic of a number of other research reports. The Goldman Sachs Group dropped their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Evercore decreased their price objective on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Raymond James Financial dropped their target price on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, Leerink Partners cut their target price on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research report on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $137.05.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $112.22 on Tuesday. The company has a market cap of $195.13 billion, a P/E ratio of 30.17, a price-to-earnings-growth ratio of 1.80 and a beta of 0.75. Abbott Laboratories has a one year low of $105.27 and a one year high of $141.23. The business has a fifty day moving average of $118.72 and a two-hundred day moving average of $126.00. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The firm had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter last year, the business earned $1.34 earnings per share. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, February 13th. Stockholders of record on Thursday, January 15th were given a $0.63 dividend. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend was Thursday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Insiders Place Their Bets

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The shares were purchased at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the purchase, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.46% of the company’s stock.

Institutional Investors Weigh In On Abbott Laboratories

Several hedge funds have recently modified their holdings of the stock. MidAtlantic Capital Management Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth $25,000. Cornerstone Financial Management LLC purchased a new stake in Abbott Laboratories during the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in Abbott Laboratories during the fourth quarter worth about $26,000. Abound Financial LLC purchased a new position in shares of Abbott Laboratories in the 4th quarter worth about $26,000. Finally, Harbor Capital Advisors Inc. acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at about $27,000. 75.18% of the stock is owned by institutional investors and hedge funds.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.